Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination
PHASE3
The purpose/aim of this study is to assess the safety and antibody response...
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China
PHASE3
The purpose of this study is to describe the safety and immunogenicity of M...
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
PHASE3
The purpose of this study was to compare the immunogenicity and describe th...
Status
Completed
Location
Birmingham Pediatric Associates Site Number : 8400026